Background and Aims Hepatoid adenocarcinoma of the stomach (HAS) is a special and rare type of gastric cancer, and there are very few studies on HAS with enough sample size. This study collected the relevant literature reports and analyzed the current status of HAS in China in recent years through a Meta-analysis of clinical data.Methods Chinese and English electronic journal databases were searched, including Wanfang Journal Full-text Database, China Biomedical Literature Database (CBM), Chinese Science and Technology Journal Database (VIP), PubMed Database. The clinical data of HAS in China were screened and extracted, and survival analysis were performed.Results A total of 294 cases of HAS reported in the literature from January 2014 to January 2021 were included in the regional analysis, and it was found that 86.4% of the reported cases were distributed in Beijing and some of the coastal areas. Among the 95 cases with complete data, 77 were males (81.1%) and 18 were females (18.9%), with an age span of 40-79 years. There were 70 patients (73.7%) with elevated serum AFP, of whom 47 cases (49.5%) had serum AFP>500 ng/mL. At the time of diagnosis, the TNM stages in 74 case were classified as stage III or IV, and 30 (31.6%) of them had liver metastases. The median survival time was only 11 months, and the 3-year cumulative survival rate was 12.4%. Women relative to men (HR=2.472, 95% CI=1.247-4.904, P=0.010), AFP>500 ng/mL (HR=1.987, 95% CI=1.073-3.677, P=0.029), palliative surgery or no versus radical surgery (HR=0.223, 95% CI=0.099-0.500, P<0.001) were independent risk factors for the prognosis of HAS.Conclusion HAS cases in China are mainly reported in Beijing and some of the coastal areas, and are rare in inland regieons. HAS is more common in middle aged and elderly men, but the prognosis in women is worse. Serum AFP>500 ng/mL is an independent risk factor for HAS. HAS is often diagnosed at an advanced stage, liver metastases are common and the overall prognosis is poor, but aggressive radical surgery may yield survival benefits.